Lipase inhibitor orlistat decreases incorporation of eicosapentaenoic and docosahexaenoic acids in rat tissues

Nutrition Research

Volumn 30, Issue 2, 2010, Pages 134-140

  Cruz Hernandez, Cristina ^a   Oliveira, Manuel ^a   Pescia, Grégory ^a   Moulin, Julie ^a   Masserey Elmelegy, Isabelle ^a   Dionisi, Fabiola ^a   Destaillats, Frédéric ^a  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Lipase; Lipid absorption; Orlistat; Rat

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY ACID; TETRAHYDROLIPSTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; ERYTHROCYTE; FOOD INTAKE; LIPID ABSORPTION; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID DIET; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN;

ANIMALS; BLOOD; DIETARY FATS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ENZYME INHIBITORS; ERYTHROCYTES; FISH OILS; INTESTINAL ABSORPTION; LACTONES; LIPASE; LIVER; MALE; RATS; RATS, WISTAR; SPLEEN;

RATTUS; RATTUS NORVEGICUS;

EID: 77951630010     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2009.12.001     Document Type: Article

References (43)

1. Padwal R., Li S.K., Lau D.C.W. Long term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obesity 2003, 27:1437-1446.
2. Drew B.S., Dixon A.F., Dixon J.B Obesity management: update on orlistat. Vasc Health Risk Manag 2007, 3:817-821.
3. Goldstein D.J. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
4. Hollander P.A., Elbein S.C., Hirsch I.B., Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288-1294.
5. Avenell A., Brown T.J., McGee M.A. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Dietet 2004, 17:291-409.
6. Padwal R.S., Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
7. Plat J., Jellema A., Ramakers J., Mensink R.P., Padwal R.S., Majumdar S.R. Weight loss, but not fish oil consumption, improves fasting and postprandial serum lipids, markers of endothelial function, and inflammatory signatures in moderately obese men. J Nutr 2007, 137:2635-2640.
8. Borgstöm B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988, 962:308-316.
9. Hadváry P., Lengsfeld H., Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem 1988, 256:357-361.
10. Zhi J., Melia A.T., Guerciolini R. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994, 56:82-85.
11. Hauptman J., Lucas C., Boldrin M.N., Collins H. Orlistat in the long-term treatment of obesity in the primary care setting. Arch Fam Med 2000, 9:160-167.
12. R. Eur J Biochem 1994, 222:395-403.
13. Luthi-Peng Q., Märki H.P., Hadváry P. Identification of the active-site serine in human pancreatic lipase by chemical modification with tetrahydrolipstatin. FEBS letters 1992, 299:111-115.
14. Asler I.L., Zehl M., Kovacić F. Mass spectrometric evidence of covalently-bound tetrahydrolipstatin at the catalytic serine of Streptomyces rimosus lipase. Biochim Biophys Acta 2007, 1770:163-170.
15. Assy N., Hussein O., Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007, 56:443-444.
16. Davidson M.H., Hauptman J., DiGirolamo M. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235-242.
17. Anderson J.W. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60 mg, over-the counter dosage. Expert Opin Pharmacother 2007, 8:1733-1742.
18. Sjöström L., Rissanen A., Andersen T., Boldrin M., Golay A., Koppeschaar H.P., et al. Lancet 1998, 352:167-172.
19. McDuffe J.R., Calis K.A., Booth S.L., Uwaifo G.I., Yanovski J.A. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002, 227:814-822.
20. Melia A.T., Koss-Twardy S.G., Zhi J. J Clin Pharmacol 1996, 36:647-653.
21. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361.
22. Goodnight S.H., Harris W.S., Connor W.E., Illingworth D.R. Polyunsaturated fatty acids, hyperlipidemia, and thrombosis. Arterioscler Thromb Vasc Biol 1982, 2:87-113.
23. Harris W.S., Muzio F. Fish oil reduces postprandial triglyceride concentrations without accelerating lipid-emulsion removal rates. Am J Clin Nutr 1993, 58:68-74.
24. Raclot T., Groscolas R., Langin D., Ferre P. Site-specific regulation of gene expression by n-3 polyunsaturated fatty acids in rat white adipose tissues. J Lipid Res 1997, 38:1963-1972.
25. Barre D.E. The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes-a mini-review. J Oleo Sci 2007, 56:319-325.
26. Lorente-Cebrián S., Pérez-Matute P., Martínez J.A., Marti A., Moreno-Aliaga M.J. Effects of eicosapentaenoic acid (EPA) on adiponectin gene expression and secretion in primary cultured rat adipocytes. J Physiol Biochem 2006, 62:61-69.
27. Pifferi F., Roux F., Langelier B. (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the brain glucose transporter GLUT1 in rats. J Nutr 2005, 135:2241-2246.
28. Whelan J., Rust C. Innovative dietary sources of n-3 fatty acids. Annu Rev Nutr 2006, 26:75-103.
29. Hill J.O., Hauptman J., Anderson J.W. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999, 69:1108-1116.
30. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
31. Cruz-Hernandez C., Deng Z., Zhou J. Methods for analysis of conjugated linoleic acids (CLA) and trans-18:1 isomers in dairy fats by using a combination of gas chromatography, silver-ion thin layer chromatography/-gas chromatography, and silver ion liquid chromatography. JAOAC Int 2004, 87:545-562.
32. Kaplan R.J., Greenwood C.E. Poor digestibility of fully hydrogenated soybean oil in rats: a potential benefit of hydrogenated fats and oils. J Nutr 1998, 128:875-880.
33. Golay P.A., Dionisi F., Hug B., Giuffrida F., Destaillats F. Direct quantification of fatty acids in dairy powders with special emphasis on trans fatty acid content. Food Chem 2006, 101:1115-1120.
34. Destaillats F., Cruz-Hernandez C. Fast analysis by gas-liquid chromatography perspective on the resolution of complex fatty acid compositions. J Chromatogr A 2007, 1169:175-178.
35. Barham J.B., Edens M.B., Fonteh A.N., Johnson M.M., Easter L., Chilton F.H. J Nutr 2000, 130:1925-1931.
36. Porsgaard T., Straarup E.M., Mu H., Høy C.E. Effect of orlistat on fat absorption in rats: a comparison of normal rats and rats with diverted bile and pancreatic juice. Lipids 2003, 38:1039-1043.
37. Kalivianakis M., Elstrodt J., Havinga R. Validation in an animal model of the carbon 13-labeled mixed triglyceride breath test for the detection of intestinal fat malabsorption. J Pediatr 1999, 135:444-450.
38. Kalivianakis M., Minich D.M., Havinga R. Detection of impaired intestinal absorption of long-chain fatty acids: validation studies of a novel test in a rat model of fat malabsorption. Am J Clin Nutr 2000, 72:174-180.
39. Nishioka T., Hafkamp A.M., Havinga R., vn Lierop P.P., Velvis H., Verkade H.J. Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats. J Pediatr 2003, 143:327-334.
40. Isler D., Moeglen C., Gains N., Meier M.K. Effect of the lipase inhibitor orlistat and of dietary lipid on the absorption of radiolabelled triolein, tri-γ-linolein and tripalmitin in mice. British J Nutr 1995, 73:851-862.
41. Parckard G.C., Birchard G.F. Traditional allometric analysis fails to provide a valid predictive model for mammalian metabolic rates. J Exp Biol 2008, 211:3581-3587.
42. Hauptman J.B., Jeunet F.S., Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992, 309S-313S.
43. Skeaff C.M., Hodson L., McKenzie J.E. Dietary-induced changes in fatty acid composition of human plasma, platelet, and erythrocyte lipids follow a similar time course. J Nutr 2006, 136:565-569.